Vorolanib

伏罗尼布

Report date: 2026/03/17 20:00:15
NME

Base Information

Drug NameVorolanib
Drug Alias NameDURAVYUTVolonibVoronib伏美纳DURAVYU™ +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 inhibitorsStem cell growth factor receptor inhibitorsPlatelet-derived growth factor receptor inhibitors +[5] 
TargetsVascular endothelial growth factor receptor 2Stem cell growth factor receptorPlatelet-derived growth factor receptor +[5] 
Therapy Area/IndicationsDiabetic macular oedemaGastroesophageal Junction NeoplasmsSolid tumours +[21] 
Global Approved IndicationsCarcinoma, Renal Cell
Approved Indications in ChinaCarcinoma, Renal Cell
Original Approved Country/TerritoryMainland China
Original Approved Date2023/06/07
Country/TerritoryCzechiaUnited StatesSlovakia +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTyrogenex Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesEyepoint Pharmaceuticals IncBetta Pharmaceuticals Co LtdAnewPharma Inc +[4] 
Inactive CompaniesXcovery Holdings,IncWashington University School Of MedicineUniversity Of Wisconsin-Madison +[5] 
Active IndicationsDiabetic macular oedemaSolid tumoursChoroidal Neovascularization +[9] 
Inactive IndicationsGastroesophageal Junction NeoplasmsMacular DegenerationRetinal Diseases +[12] 

Other Information

ATC CodeN/A
Related LinksDrugBank